Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33052557)

  • 1. The novel low molecular weight MYC antagonist MYCMI-6 inhibits proliferation and induces apoptosis in breast cancer cells.
    AlSultan D; Kavanagh E; O'Grady S; Eustace AJ; Castell A; Larsson LG; Crown J; Madden SF; Duffy MJ
    Invest New Drugs; 2021 Apr; 39(2):587-594. PubMed ID: 33052557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: MAX Interaction and Tumor Growth in a MYC-Dependent Manner.
    Castell A; Yan Q; Fawkner K; Bazzar W; Zhang F; Wickstr├Âm M; Alzrigat M; Franco M; Krona C; Cameron DP; Dyberg C; Olsen TK; Verschut V; Schmidt L; Lim SY; Mahmoud L; Hydbring P; Lehmann S; Baranello L; Nelander S; Johnsen JI; Larsson LG
    Cancer Res Commun; 2022 Mar; 2(3):182-201. PubMed ID: 36874405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A selective high affinity MYC-binding compound inhibits MYC:MAX interaction and MYC-dependent tumor cell proliferation.
    Castell A; Yan Q; Fawkner K; Hydbring P; Zhang F; Verschut V; Franco M; Zakaria SM; Bazzar W; Goodwin J; Zinzalla G; Larsson LG
    Sci Rep; 2018 Jul; 8(1):10064. PubMed ID: 29968736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer.
    Tanioka M; Mott KR; Hollern DP; Fan C; Darr DB; Perou CM
    Genome Med; 2018 Nov; 10(1):86. PubMed ID: 30497520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-myc gene expression alone is sufficient to confer resistance to antiestrogen in human breast cancer cells.
    Venditti M; Iwasiow B; Orr FW; Shiu RP
    Int J Cancer; 2002 May; 99(1):35-42. PubMed ID: 11948489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
    Kang J; Sergio CM; Sutherland RL; Musgrove EA
    BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic activity of letrozole and sorafenib on breast cancer cells.
    Bonelli MA; Fumarola C; Alfieri RR; La Monica S; Cavazzoni A; Galetti M; Gatti R; Belletti S; Harris AL; Fox SB; Evans DB; Dowsett M; Martin LA; Bottini A; Generali D; Petronini PG
    Breast Cancer Res Treat; 2010 Nov; 124(1):79-88. PubMed ID: 20054642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate.
    Shiang CY; Qi Y; Wang B; Lazar V; Wang J; Fraser Symmans W; Hortobagyi GN; Andre F; Pusztai L
    Breast Cancer Res Treat; 2010 Oct; 123(3):747-55. PubMed ID: 20024612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.
    Sun K; Atoyan R; Borek MA; Dellarocca S; Samson ME; Ma AW; Xu GX; Patterson T; Tuck DP; Viner JL; Fattaey A; Wang J
    Mol Cancer Ther; 2017 Feb; 16(2):285-299. PubMed ID: 27980108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ╬▓-catenin regulates c-Myc and CDKN1A expression in breast cancer cells.
    Xu J; Chen Y; Huo D; Khramtsov A; Khramtsova G; Zhang C; Goss KH; Olopade OI
    Mol Carcinog; 2016 May; 55(5):431-9. PubMed ID: 25663530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.
    Helfrich BA; Kim J; Gao D; Chan DC; Zhang Z; Tan AC; Bunn PA
    Mol Cancer Ther; 2016 Oct; 15(10):2314-2322. PubMed ID: 27496133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975.
    Tang M; O'Grady S; Crown J; Duffy MJ
    Breast Cancer Res Treat; 2022 Sep; 195(2):105-115. PubMed ID: 35908121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.
    Synnott NC; Bauer MR; Madden S; Murray A; Klinger R; O'Donovan N; O'Connor D; Gallagher WM; Crown J; Fersht AR; Duffy MJ
    Cancer Lett; 2018 Feb; 414():99-106. PubMed ID: 29069577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression.
    Daga M; Pizzimenti S; Dianzani C; Cucci MA; Cavalli R; Grattarola M; Ferrara B; Scariot V; Trotta F; Barrera G
    Phytomedicine; 2019 Mar; 56():156-164. PubMed ID: 30668336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.
    Finn RS; Dering J; Conklin D; Kalous O; Cohen DJ; Desai AJ; Ginther C; Atefi M; Chen I; Fowst C; Los G; Slamon DJ
    Breast Cancer Res; 2009; 11(5):R77. PubMed ID: 19874578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of cell proliferation, induction of apoptosis, reactivation of DLC1, and modulation of other gene expression by dietary flavone in breast cancer cell lines.
    Ullmannova V; Popescu NC
    Cancer Detect Prev; 2007; 31(2):110-8. PubMed ID: 17418982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC.
    Griffin NI; Sharma G; Zhao X; Mirza S; Srivastava S; Dave BJ; Aleskandarany M; Rakha E; Mohibi S; Band H; Band V
    Breast Cancer Res; 2016 Nov; 18(1):113. PubMed ID: 27852327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dicyano compound induces autophagic or apoptotic cell death via Twist/c-Myc axis depending on metastatic characteristics of breast cancer cells.
    Alvur O; Kucuksayan H; Baygu Y; Kabay N; Gok Y; Akca H
    Mol Biol Rep; 2022 Jan; 49(1):39-50. PubMed ID: 34775571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
    Greer YE; Gilbert SF; Gril B; Narwal R; Peacock Brooks DL; Tice DA; Steeg PS; Lipkowitz S
    Breast Cancer Res; 2019 Feb; 21(1):27. PubMed ID: 30777098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc/miR-29b-3p/CDK6 axis.
    Ji W; Zhang W; Wang X; Shi Y; Yang F; Xie H; Zhou W; Wang S; Guan X
    Cell Death Dis; 2020 Sep; 11(9):760. PubMed ID: 32934206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.